Kadmus Pharmaceuticals (FAAH Inhibitor Technology OSS) is Buildings and Property in United States that focus on compound library business. They cover business area such as control, fatty acid amide hydrolase technology, -ready compound, exclusive license, California, Irvine, patent, novel second generation FAAH inhibitor, endogenous signal lipid, (CB, their effect.
-
Compound Library
-
101 Theory
Suite 100
Irvine, CA 92617
United States
Private
controlfatty acid amide hydrolase technology-ready compoundexclusive licenseCaliforniaIrvinepatentnovel second generation FAAH inhibitorendogenous signal lipid(CBtheir effect
* We use standard office opening hours in near Kadmus Pharmaceuticals (FAAH Inhibitor Technology OSS)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Kadmus Pharmaceuticals (FAAH Inhibitor Technology OSS) is Buildings and Property business from United States that founded in - ( years old in ), Kadmus Pharmaceuticals (FAAH Inhibitor Technology OSS) business is focusing on Compound Library.
Kadmus Pharmaceuticals (FAAH Inhibitor Technology OSS) headquarter office and corporate office address is located in 101 Theory Suite 100 Irvine, CA 92617 United States.
Kadmus Pharmaceuticals (FAAH Inhibitor Technology OSS) was founded in United States.
In , Kadmus Pharmaceuticals (FAAH Inhibitor Technology OSS) is currently focus on compound library sector.
Above is snippet of Google Trends for "compound library" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Kadmus Pharmaceuticals (FAAH Inhibitor Technology OSS), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
